The Potential Impact of Maintaining a 3-Hour IV Thrombolysis Window: How Many More Patients can we Safely Treat?

BACKGROUND: In 2008, the European Cooperative Acute Stroke Study-3 (ECASS-3) demonstrated that intravenous-tissue plasminogen activator could be safely administered for acute stroke patients presenting between 3 and 4.5 hours from symptom onset. Recently, the Food and Drug Administration rejected ex...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Lyerly, Michael J., Albright, Karen C., Boehme, Amelia K., Shahripour, Reza Bavarsad, Houston, James T., Rawal, Pawan V., Kapoor, Niren, Alvi, Muhammad, Sisson, April, Alexandrov, Anne W., Alexandrov, Andrei V.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2013
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3901990/
https://ncbi.nlm.nih.gov/pubmed/24471140
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items